providence Biotechnology  banner
 
Home | About us | Products | Technology | Management | Contact us

Company Summary

Providence biotechnology According to the Prescription Pricing Authority, in 2005, £341 million was spent on anti-inflammatory drugs. Problems associated with the current treatment modalities for IA are well documented.

In light of the recent demise of COX-2 inhibitors, researchers are constantly looking for new ways to reduce the adverse reactions associated with all types of anti-inflammatory medicines.

Arthroderm Duo™ drug delivery system will provide the active ingredients direct to the source of pain, eliminating first pass metabolism and reducing the overall systemic effects of the anti-inflammatory medicines.

Objectives
The principal objectives of PBS are:
Providence Bio Technology To provide improved pain relief to patients with IA

Providence Bio TechnologyTo achieve 2% market penetration in the anti-inflammatory drug market

Providence Bio TechnologyTo provide value for stakeholder investment
 
 
Facts
providenceAccording to the Prescription Pricing Authority, in 2005, £341 million was spent on anti-inflammatory drugs in the UK.
Providence
 
Providence Biotechnology
   
  ©2007 Providence Biotechnology Solutions Ltd . All Rights Reserved
home about us products technology contacts
home about us products technology contacts